Tarsus Pharmaceuticals Inc (TARS) Stock Analysis
Verdict: WATCH (do not buy)
Rapid XDEMVY commercial scale and 90%+ gross margins drive near-term profitability, but capped analyst upside limits near-term entry.
Investment score: 56/100
Analysis as of
Is Tarsus Pharmaceuticals Inc stock worth reviewing? AI model thesis
Tarsus demonstrates excellent commercial execution with XDEMVY, but a P/S of 6.44x and proximity to its 52W high ($91.53) lead the model to view TARS as a Hold.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Tarsus Pharmaceuticals Inc opportunities and risks
What speaks for TARS
- Rapid commercial adoption of XDEMVY in Demodex blepharitis
What speaks against TARS
- Concentration risk in a single commercial therapy (XDEMVY)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| TARS | n/a | 6.4x | n/a | 90.6% | -7.7% | 1.6% |
| EWTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.4% |
| ELVN | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.6% |
| AMLX | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| INDV | 12.3x | 3.3x | 10.8x | 83.9% | 26.7% | -2.5% |
| MANE | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.5% |
Frequently asked questions about Tarsus Pharmaceuticals Inc (TARS)
Is TARS stock a good investment?
The cached TradeMates AI model rates Tarsus Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 56/100. Tarsus demonstrates excellent commercial execution with XDEMVY, but a P/S of 6.44x and proximity to its 52W high ($91.53) lead the model to view TARS as a Hold. This is algorithmic model output, not personal investment advice.
Is TARS stock a buy?
The TradeMates model verdict for TARS is WATCH (do not buy) with an investment score of 56/100. Treat this as a model signal to review, not a personal buy recommendation.